BLUE - bluebird bio, Inc. Short-Term Debt to Capital

bluebird bio, Inc. (BLUE) is building a comprehensive infrastructure for treating rare pathologies, offering patients a full cycle of gene correction. Strong interest from medical centers in such innovations and the expansion of insurance coverage are driving demand growth. This chart on GURU.Markets, where the indicator stands at 0.00, confirms the potential of bluebird bio, Inc. (BLUE), whose profits rely on exclusive patents in the therapy of hereditary blood diseases.

With stable bioreactor utilization and the maintenance of cryogenic storage according to industry standards, the ratio of short-term liabilities to equity for bluebird bio, Inc. (BLUE), equal to 0.00, reflects the operating cycle's dependence on short-term loans. This coefficient measures the share of obligations maturing within one year relative to equity, where an increase in the indicator signals liquidity risks, while a decrease confirms the issuer's financial autonomy.